Gilead: Hep-C Scripts Go Down To The Wire - Barron's
For Gilead Sciences (NASDAQ:GILD), one of the challenges during the past three months has been meeting analysts' sky-target for the number of prescriptions written for its hepatitis-C drugs Harvoni and Sovaldi. After a large surge last week, it's going to be close. Evercore ISI's Mark Schoenebaum explains:
Harvoni Total Prescriptions = 5,642 (up +44.9% from last week and up 29% from TWO weeks ago [i.e. week prior to T-giving])
Sovaldi Total Prescriptions = 3,553 (up +31.6% from last week and up 3% from TWO weeks ago)
[Harvoni & Sovaldi] total prescriptions need to equal around 85k scrips in the 4Q to hit numbers, and thus far total prescriptions totals about 62K (there are 4 more weeks left in qtr). Sovaldi + Harvoni IMS scripts need to average around ~6,500 in 4Q to hit current US hep C consensus estimate of $2.75B sales; at this point, the average is 6,597.
Disclosure: The author is long GILD.